Upping expectations, Sanofi makes its case on why Dupixent will go on to $14.5B in peak sales — whatever Eli Lilly may have on its mind

Over the weekend, Eli Lilly laid out some solid Phase III reasons why the pharma giant thinks it can take on Regeneron and Sanofi’s Dupixent …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Up­ping ex­pec­ta­tions, Sanofi makes its case on why Dupix­ent will go on to $14.5B in peak sales — what­ev­er Eli Lil­ly may have on its mind